7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Integrated data from three double-blind, randomized, placebo-controlled trials were analyzed to evaluate the efficacy and tolerability of ezogabine (EZG; US adopted name)/retigabine (RTG; international non-proprietary name) when used in combination with ≥1 sodium channel blocking antiepileptic drug (AED), ≥1 non-sodium channel blocking AED, or ≥1 AED from both the sodium channel and non-sodium channel mechanistic groups. Efficacy and tolerability appeared to be similar across all three groups of patients.

          Related collections

          Author and article information

          Journal
          Epilepsy Res.
          Epilepsy research
          Elsevier BV
          1872-6844
          0920-1211
          Jul 2014
          : 108
          : 5
          Affiliations
          [1 ] Epilepsy Unit, Western Infirmary, University of Glasgow, Glasgow, UK. Electronic address: Martin.Brodie@glasgow.ac.uk.
          [2 ] Comprehensive Epilepsy Center, Department of Neurology, New York University, New York, NY, USA. Electronic address: Jacqueline.French@nyumc.org.
          [3 ] GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: susan.a.mcdonald@gsk.com.
          [4 ] GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: wen-jene.k.lee@gsk.com.
          [5 ] GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: bryan.e.adams@gsk.com.
          [6 ] Valeant Pharmaceuticals North America, Durham, NC, USA. Electronic address: andrew.scott@valeant.com.
          [7 ] Valeant Pharmaceuticals North America, Durham, NC, USA. Electronic address: vnohria@aol.com.
          [8 ] GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: sarah.e.derossett@gsk.com.
          Article
          S0920-1211(14)00082-5
          10.1016/j.eplepsyres.2014.03.008
          24726452
          ae9c86e5-0c49-4d7d-acd5-ed0a2d220950
          History

          Antiepileptic drugs,Tolerability,Retigabine,Rational polytherapy,Ezogabine,Efficacy

          Comments

          Comment on this article